Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
See all formats and pricing
More options …
Volume 6, Issue 5


Volume 10 (2015)

Comparison of prostate cancer patient’s survival in Belarus and Lithuania

Giedre Smailyte / Yury Averkin / Ilya Veyalkin / Sergey Krasny / Karolis Ulinskas
Published Online: 2011-08-09 | DOI: https://doi.org/10.2478/s11536-011-0058-5
  • [1] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food. Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.200700511Web of ScienceCrossrefGoogle Scholar

  • [2] Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P., Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581–592. http://dx.doi.org/10.1093/annonc/mdl498CrossrefGoogle Scholar

  • [3] Coebergh J.W.W., Sant M., Berrino F., Verdecchia A., Survival of adult cancer patients in Europe diagnosed from 1978–1989: the EUROCARE II study, Eur. J. Cancer, 1998, 34, 2137–2178. http://dx.doi.org/10.1016/S0959-8049(98)99063-3CrossrefGoogle Scholar

  • [4] Berrino F., Capocaccia R., Coleman M.P., Estève J., Gatta G., Hakulinen T., et al., Survival of cancer patients in Europe. The EUROCARE-3 study, Annal. Oncol., 2003, 14(suppl 5), v9–155. http://dx.doi.org/10.1093/annonc/mdg750CrossrefGoogle Scholar

  • [5] Coleman M.P., Gatta G., Verdecchia A., Estève J., Sant M., Storm H., et al., EUROCARE-3 summary: cancer survival at the end of 20th century, Annal. Oncol., 2003, 14(suppl 5), v128–149. http://dx.doi.org/10.1093/annonc/mdg756CrossrefGoogle Scholar

  • [6] Ederer F., Axtell L.M., Cutler S.J., The relative survival rate: a statistical methodology, Natl. Cancer Inst. Monogr., 1961, 6, 101–121 PubMedGoogle Scholar

  • [7] Dickman P., [Accessed 29 June 2009], Available at http://www.pauldickman.com. Google Scholar

  • [8] Sant M, Capocaccia R, Coleman MP, Berrino F., Gatta G., Micheli A., et al., Cancer survival increases in Europe, but international differences remain wide, Eur. J. Cancer, 2001, 37, 1659–1667. http://dx.doi.org/10.1016/S0959-8049(01)00206-4CrossrefGoogle Scholar

  • [9] Verdecchia A., Francisci S., Brenner H., Gatta G., Micheli A., Mangone L., et al., Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data, Lancet Oncol., 2007, 8, 784–796. http://dx.doi.org/10.1016/S1470-2045(07)70246-2Google Scholar

  • [10] Gondos A., Bray F., Brewster D.H., Coebergh J.W., Hakulinen T., Janssen-Heijnen M.L., et al., Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries, Eur. J. Cancer, 2008, 44, 1463–1475. http://dx.doi.org/10.1016/j.ejca.2008.03.010CrossrefGoogle Scholar

  • [11] Jemal A., Clegg L.X., Ward E., Ries L.A., Wu X., Jamison P.M., et al., Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival, Cancer, 2004, 101, 3–27. http://dx.doi.org/10.1002/cncr.20288CrossrefGoogle Scholar

  • [12] Verdecchia A., Guzzinati S., Francisci S., De Angelis R., Bray F., Allemani C., et al., Survival trends in European cancer patients diagnosed from 1988 to 1999, Eur. J. Cancer, 2009, 45, 1042–1066. http://dx.doi.org/10.1016/j.ejca.2008.11.029CrossrefGoogle Scholar

  • [13] Brenner H., Arndt V., Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis, J. Clin. Oncol., 2005, 23, 441–447. http://dx.doi.org/10.1200/JCO.2005.11.148CrossrefGoogle Scholar

  • [14] Gondos A., Bray F., Hakulinen T., Brenner H., Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis, Ann. Oncol., 2009, 20, 564–573. http://dx.doi.org/10.1093/annonc/mdn639CrossrefWeb of ScienceGoogle Scholar

  • [15] D’Ambrosio G., Samani F., Cancian M., De Mola C., Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database, Eur. J. Cancer Prev., 2004, 13, 383–386. http://dx.doi.org/10.1097/00008469-200410000-00005CrossrefGoogle Scholar

  • [16] Etzioni R., Penson D.F., Legler J.M., Overdiagnosis due to prostate specific antigen screening: lessons from U.S. prostate cancer incidence trends, J. Natl. Cancer Inst., 2002, 94, 981–990. CrossrefGoogle Scholar

  • [17] Gavin A., McCarron P., Middleton R.J., Savage G., Catney D., O’Reilly D., et al., Evidence of prostate cancer screening in a UK region, BJU Int., 2004, 93, 730–734. http://dx.doi.org/10.1111/j.1464-410X.2003.04716.xCrossrefGoogle Scholar

  • [18] Kumar S., Shelley M., Harrison C., Coles B., Wilt T.J., Mason M.D., Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer, Cochrane Database Syst. Rev., [2006CD006019]. Google Scholar

  • [19] Mike S., Harrison C., Coles B., Staffurth J., Wilt T.J., Mason M.D., Chemotherapy for hormone-refractory prostate cancer, Cochrane Database Syst. Rev., [2006CD005247]. Google Scholar

  • [20] Baade P.D., Youlden D.R., Krnjacki L.J., International epidemiology of prostate cancer: geographical distribution and secular trends, Mol. Nutr. Food Res., 2009, 53, 171–184. http://dx.doi.org/10.1002/mnfr.200700511Web of ScienceCrossrefGoogle Scholar

About the article

Published Online: 2011-08-09

Published in Print: 2011-10-01

Citation Information: Open Medicine, Volume 6, Issue 5, Pages 545–549, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-011-0058-5.

Export Citation

© 2011 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in